Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2021

Feb 24, 2021

30016_dirs_2021-02-24_30d71789-74da-4c6a-900a-f9af21d2d879.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-02-22

Reporting Person: JUNIUS DANIEL M (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-22 Common Stock M 898 $79.54 Acquired 3773 Direct
2021-02-22 Common Stock M 1000 $85 Acquired 4773 Direct
2021-02-22 Common Stock S 10 $539.19 Disposed 4763 Direct
2021-02-22 Common Stock S 1888 $538.5673 Disposed 2875 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-22 Incentive Stock Option (right-to-buy) $79.54 M 898 Disposed 2025-02-13 Common Stock (898) Direct
2021-02-22 Non-Qualified Stock Option (right-to-buy) $85 M 1000 Disposed 2026-05-03 Common Stock (1000) Direct

Footnotes

F1: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 449 shares on May 6, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F2: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2017 annual meeting of shareholders.

F3: Not applicable.